Pharma & biotech

Bernie Sanders urges Novo Nordisk and Sanofi to follow Eli Lilly's example: Drop insulin prices

The chair of the senate health committee says “unacceptable corporate greed” is why insulin prices have risen 1,000% since 1996 in letters addressed to CEOs of Novo Nordisk and Sanofi.
Bernie Sanders, Vermont Senator and chair of the US senate health committee, urges fellow insulin makers Novo Nordisk and Sanofi to lower prices like Eli Lilly | Photo: Anna Moneymaker/AFP/Ritzau Scanpix
Bernie Sanders, Vermont Senator and chair of the US senate health committee, urges fellow insulin makers Novo Nordisk and Sanofi to lower prices like Eli Lilly | Photo: Anna Moneymaker/AFP/Ritzau Scanpix
by albert rønning-andersson, translated by daniel pedersen

Bernie Sanders has in his capacity as chair of the US senate health committee trained his sights, again, on pharmaceutical companies Novo Nordisk and Sanofi concerning both drugmakers’ insulin prices, reports industry media Endpoints News.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Jobs